UK markets closed

Roche Holding AG (RHHBF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
426.86+0.11 (+0.03%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close426.75
Open426.86
Bid0.00 x 0
Ask0.00 x 0
Day's range426.86 - 426.86
52-week range320.00 - 473.65
Volume1
Avg. volume132
Market cap337.425B
Beta (5Y monthly)0.29
PE ratio (TTM)24.13
EPS (TTM)17.69
Earnings dateN/A
Forward dividend & yield9.78 (2.29%)
Ex-dividend date18 Mar 2021
1y target estN/A
  • Motley Fool

    Why Atea Pharmaceuticals Stock Got Crushed This Week

    Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).

  • Reuters

    Roche's implant for chronic eye disorder wins U.S. approval

    (Reuters) -Roche Holding AG on Friday won approval from the U.S. health regulator for its eye implant to treat a chronic disorder causing blurred vision, giving patients an alternative to receiving monthly eye injections with existing treatments. The surgically implantable device Susvimo is intended to treat wet age-related macular degeneration (wet AMD), a disorder caused by the leak of fluid or blood from abnormal blood vessels into an area near the retina called the macula. The device is designed to continuously deliver a customized version of the Swiss company's drug ranibizumab, branded as Lucentis, which is an anti-vascular endothelial growth factor (anti-VEGF) therapy.

  • Globe Newswire

    FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)

    Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a monthBy continuously delivering medicine into the eye through a refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments per yearNeovascular AMD impacts approximately 20 million people worldwide and is a leading cause of blindness in people over the age of 6